These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38081808)

  • 21. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
    Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
    Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
    Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
    Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
    [No Abstract]   [Full Text] [Related]  

  • 23. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
    Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
    J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 26. IKKα inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
    Liao J; Qin QH; Lv FY; Huang Z; Lian B; Wei CY; Mo QG; Tan QX
    Sci Rep; 2023 Apr; 13(1):6211. PubMed ID: 37069240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceritinib is a novel triple negative breast cancer therapeutic agent.
    Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
    Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.
    Li F; Niu M; Qin K; Guo R; Yi Y; Xu J; Li L; Xie S; Fu M; Wen N; Liao W; Xiao ZJ
    Oncogene; 2023 Jan; 42(5):339-350. PubMed ID: 36460773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial dynamics as a novel treatment strategy for triple-negative breast cancer.
    Wang Y; Harada-Shoji N; Kitamura N; Yamazaki Y; Ebata A; Amari M; Watanabe M; Miyashita M; Tada H; Abe T; Suzuki T; Gonda K; Ishida T
    Cancer Med; 2024 Jan; 13(2):e6987. PubMed ID: 38334464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
    Bano A; Stevens JH; Modi PS; Gustafsson JÅ; Strom AM
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
    Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
    Samanta D; Gilkes DM; Chaturvedi P; Xiang L; Semenza GL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5429-38. PubMed ID: 25453096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
    Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
    PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration.
    Xiao H; Yang X; Huang S
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):43-52. PubMed ID: 36436062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mint3-mediated L1CAM expression in fibroblasts promotes cancer cell proliferation via integrin α5β1 and tumour growth.
    Nakaoka HJ; Tanei Z; Hara T; Weng JS; Kanamori A; Hayashi T; Sato H; Orimo A; Otsuji K; Tada K; Morikawa T; Sasaki T; Fukayama M; Seiki M; Murakami Y; Sakamoto T
    Oncogenesis; 2017 May; 6(5):e334. PubMed ID: 28504692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells
    Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O
    Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.